Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. - Wikidata - wikimedia - TriplyDB

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.

http://www.wikidata.org/entity/Q33402047

about

Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency Current therapeutic strategies and novel approaches in osteosarcoma.Uncovering metabolism in rhabdomyosarcoma.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.

P2860

Q26750631-8FDB57D0-8C50-4E13-9BDD-B4639DF8306A Q35135650-8F55716D-AFE2-4965-B983-7F27BEE0DF8D Q37048013-3F5E55DE-C2D3-4353-9AA9-273E24D32E64 Q38161735-CF5F474E-5C55-4884-8787-B63982F979BF Q38553827-A7E24F33-24EE-45C4-BDD0-B1F4FA49DA78 Q38809116-CCA9CA0C-9CF4-4FDF-B5E6-1463125DAFF3 Q40041609-B325D6E7-8100-47D8-8BB6-47706464F4FB Q40129131-D6045F3D-23F9-4BBD-A802-C0C4C9BBFBB4 Q47133403-9D940254-7274-43AE-B1F7-776FDCC0500D Q48101407-2E87C7C4-E084-427A-9929-B6CC62BBA561

P2860

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.

http://www.wikidata.org/entity/Q33402047

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@ast

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@en

type

label

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@ast

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@en

prefLabel

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@ast

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@en

P1433

Q33402047-CD42A277-92DD-42AB-BA72-91CAB948F024

P1476

Q33402047-4A1B233B-A313-46E7-9DF8-556B946A0771

P2093

Q33402047-43958233-85A4-46B8-BA12-E1E60BE5217F

Q33402047-7E4AAEF0-9227-4B6B-B982-0F5C5AEB79B9

Q33402047-837E3736-A4A6-4A21-A593-444C41EDE581

Q33402047-B4FF4574-67F9-4A1C-B482-79A4E7F6B4CA

Q33402047-D32D4735-B99F-441A-821B-2C37C82E3316

Q33402047-D3CA9B45-3539-4DB5-A459-4227B8B7AA30

Q33402047-D6FEA86D-804D-4056-B87E-BE4770D82136

P2860

Q33402047-092BCACB-2502-4C08-BAC5-1DCE64069BD2

Q33402047-09BA3F76-2663-409C-BBC6-445F4B8E0449

Q33402047-0FBA1405-8961-49E9-A8B8-1A3628DEC0A0

Q33402047-16F94015-6A7B-4D24-9751-98F7851D5BB7

Q33402047-531F2126-D3F6-4FB8-B51D-D0C14D25CAF8

Q33402047-5BF4075E-219A-49A9-8999-2EF86087F71B

Q33402047-62A31E02-0699-4E54-8FB9-290B040A51BB

Q33402047-658E15C0-7958-4F96-B6DC-CA9621C76D59

Q33402047-73CA5C8C-EB8F-43B1-B4D2-05BD520BB9D5

Q33402047-78442126-EEEA-43CE-B8C2-4E2E1C0F5ED3

P304

Q33402047-32F0A72B-FFC4-46F8-BCEC-6CC076A68394

P31

Q33402047-09919C7E-FDB9-465A-8CBC-E4617445999A

P356

Q33402047-1D483579-2DAD-4EB1-B480-CC967AEC74FA

P433

Q33402047-07CEC0A7-4145-43E5-80E7-DA75DF35F119

P478

Q33402047-593DAD9C-5820-43F3-9D69-33C2904C951A

P50

Q33402047-25466890-B889-4F80-8A66-2B64C82AD350

Q33402047-B8198942-629F-4E39-A6F3-B0312CE15496

P577

Q33402047-90913A04-3D0B-4378-AA45-91743C466A0B

P698

Q33402047-076A9523-A175-448E-89E5-52C1569F8C99

P921

Q33402047-3451A4DC-559B-4289-919A-5D0A003A0872

Q33402047-713660E1-3BCB-4717-9FAB-9C410D3EFE82

P932

Q33402047-AFE21CED-49E9-47F3-9629-EC34AAECFDE7

P356

P1433

Pediatric Blood & Cancer

P1476

Phase 2 trial of pemetrexed in ...... ildren's Oncology Group study.

@en

P2093

Allen Melemed

http://www.w3.org/2001/XMLSchema#string

Anne B Warwick

http://www.w3.org/2001/XMLSchema#string

Mark Krailo

http://www.w3.org/2001/XMLSchema#string

Matthew M Ames

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Stephanie L Safgren

http://www.w3.org/2001/XMLSchema#string

Suman Malempati

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Folic acid food fortification is associated with a decline in neuroblastoma

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

Phase I trials of pemetrexed.

Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.

FDA drug approval summaries: pemetrexed (Alimta).

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).

P304

237-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24244

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2012-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22745043

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3463652

http://www.w3.org/2001/XMLSchema#string